FOX01-rictor AXIS induces AKT phosporylation during CLL cell adaptation to BCR inhibitors: Implications for combinatorial therapy.

• Autoři: ONDRIŠOVÁ Laura; ŠEDA Václav; HOFERKOVÁ Eva; CHIODIN G.; HLAVÁČ Kryštof; KOŠŤÁLOVÁ Lenka; MLADONICKÁ PAVLASOVÁ Gabriela; FILIP Daniel; FARIA ZENI Pedro; OPPELT Jan; PANOVSKÁ Anna; PLEVOVÁ Karla; POSPÍŠILOVÁ Šárka; SIMKOVIC M.; VRBACKÝ F.; LYSÁK Daniel; FERNANDES SM.; DAVIDS MS.; MAIQUES-DIAZ A.; CHARALAMPOPOULOU S.; MARTIN-SUBERO JI.; BROWN JR.; DOUBEK Michael; FORCONI F.; MAYER Jiří; MRÁZ Marek
• Rok publikování: 2023
• Druh: Konferenční abstrakty
• Fakulta / Pracoviště MU: Středoevropský technologický institut

Přiložené soubory

• Hematological_Oncology_-_2023_-_Ondrisova_-_FOXO1_RICTOR_AXIS_INDUCES_AKT_PHOSPHORYLATION_DURING_CLL_CELL_ADAPTATION_TO_BCR.pdf

• Popis: Although genetic mechanisms of resistance to BCR inhibitors in CLL are well-known, it remains elusive whether non genetic adaptation mechanisms might exist. We focused on the possible role of Akt pathway as PI3K-Akt activation is the only known factor that rescues the apoptosis induced by BCR deletionin mature Bcells in mouse models. We performed transcriptome profiling (Illumina) and analyzed samples obtained from CLL patients before andduring ibrutinib or idelalisib therapy (1–12weeks of therapy, n=70 patients with 194samples) and performed gene editing in MEC1 cells to reveal the functional role of FoxO1/Rictor.

Související projekty

• Signaling propensity in the microenvironment of B cell chronic lymphocytic leukemia
• Národní ústav pro výzkum rakoviny
• Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit X